# Merck & Co., Inc.: overview

MRK · NYSE · CIK 310158 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/mrk.md) · [Financials](/companies/mrk/financials.md) · [Filings](/companies/mrk/filings.md) · [Insiders](/companies/mrk/insiders.md)

Latest reported revenue: [$16.61bn](/filings/0000310158-26-000212.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 7, 2026 (XBRL us-gaap:Revenues, accession 0000310158-26-000212).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $bn | [16.7](/filings/0000310158-25-000059.md) | [15.6 d](/filings/0000310158-26-000063.md) | [15.5](/filings/0001628280-26-029802.md) | [15.8](/filings/0000310158-26-000212.md) | [17.3](/filings/0000310158-25-000059.md) | [16.4 d](/filings/0000310158-26-000063.md) | [16.3](/filings/0001628280-26-029802.md) | [16.6](/filings/0000310158-26-000212.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net margin | % | [19.0%](/filings/0000310158-25-000059.md) | [24.0% d](/filings/0000310158-26-000063.md) | [32.7%](/filings/0001628280-26-029802.md) | [28.0%](/filings/0000310158-26-000212.md) | [33.5%](/filings/0000310158-25-000059.md) | [18.1% d](/filings/0000310158-26-000063.md) | [(26.0%)](/filings/0001628280-26-029802.md) | [(8.0%)](/filings/0000310158-26-000212.md) |
| Diluted EPS | $ per share | [1.24](/filings/0000310158-25-000059.md) | not reported | [2.01](/filings/0001628280-26-029802.md) | [1.76](/filings/0000310158-26-000212.md) | [2.32](/filings/0000310158-25-000059.md) | not reported | [(1.72)](/filings/0001628280-26-029802.md) | [(0.54)](/filings/0000310158-26-000212.md) |
| Free cash flow | $bn | [8.5 d](/filings/0000310158-25-000059.md) | [2.5 d](/filings/0000310158-26-000063.md) | [1.2](/filings/0001628280-26-029802.md) | [2.5 d](/filings/0000310158-26-000212.md) | [6.8 d](/filings/0000310158-25-000059.md) | [1.8 d](/filings/0000310158-26-000063.md) | [2.9](/filings/0001628280-26-029802.md) | [4.5 d](/filings/0000310158-26-000212.md) |

- Revenue. XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $bn | [48.7](/filings/0001628280-24-006850.md) | [59.3](/filings/0001628280-25-007732.md) | [60.1](/filings/0000310158-26-000063.md) | [64.2](/filings/0000310158-26-000063.md) | [65.0](/filings/0000310158-26-000063.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | not reported | not reported | not reported | not reported | not reported |
| Net margin | % | [26.8%](/filings/0001628280-24-006850.md) | [24.5%](/filings/0001628280-25-007732.md) | [0.6%](/filings/0000310158-26-000063.md) | [26.7%](/filings/0000310158-26-000063.md) | [28.1%](/filings/0000310158-26-000063.md) |
| Diluted EPS | $ per share | [5.14](/filings/0001628280-24-006850.md) | [5.71](/filings/0001628280-25-007732.md) | [0.14](/filings/0000310158-26-000063.md) | [6.74](/filings/0000310158-26-000063.md) | [7.28](/filings/0000310158-26-000063.md) |
| Free cash flow | $bn | [8.7](/filings/0001628280-24-006850.md) | [14.7](/filings/0001628280-25-007732.md) | [9.1](/filings/0000310158-26-000063.md) | [18.1](/filings/0000310158-26-000063.md) | [12.4](/filings/0000310158-26-000063.md) |

- Revenue. XBRL Revenue: us-gaap:Revenues.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues.
- Operating margin (operating income / revenue). XBRL Revenue: us-gaap:Revenues.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment; Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/mrk/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $29.17bn | 226,999,837 |  | Added +1,169,507 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $20.73bn | 161,323,174 |  | Added +335,550 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $15.57bn | 120,413,256 |  | Added +1,087,583 |
| [WELLINGTON MANAGEMENT GROUP LLP](/funds/902219.md) | 2026-06-30 | $11.08bn | 86,249,283 |  | Added +1,934,312 |
| [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $8.70bn | 67,738,969 |  | Added +434,664 |
| [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $7.79bn | 60,744,214 |  | Added +1,186,060 |
| [CHARLES SCHWAB INVESTMENT MANAGEMENT INC](/funds/884546.md) | 2026-06-30 | $6.99bn | 54,365,289 |  | Added +4,600,064 |
| [MORGAN STANLEY](/funds/895421.md) | 2026-06-30 | $6.25bn | 48,641,158 |  | Added +1,008,671 |
| [FMR LLC](/funds/315066.md) | 2026-06-30 | $5.84bn | 45,440,355 |  | Added +924,345 |
| [JPMORGAN CHASE & CO](/funds/19617.md) | 2026-06-30 | $5.68bn | 43,886,420 |  | Reduced −9,086,563 |

## Recent filings

[All 2,265 filings](/companies/mrk/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-10-29 | 06:43 ET | [8-K](/filings/0001104659-26-119825.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-26-119825 |
| 2026-10-13 | 12:36 ET | [8-K](/filings/0000310158-26-000237.md) | 5.02 Departure or appointment of officers or directors | 0000310158-26-000237 |
| 2026-08-07 | 16:11 ET | [10-Q](/filings/0000310158-26-000212.md) | Quarterly report, period 2026-06-30 | 0000310158-26-000212 |
| 2026-08-04 | 06:47 ET | [8-K](/filings/0001104659-26-090045.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-26-090045 |
| 2026-05-28 | 16:15 ET | [8-K](/filings/0001104659-26-067509.md) | 5.07 Shareholder vote results | 0001104659-26-067509 |
| 2026-05-22 | 16:21 ET | [8-K](/filings/0001628280-26-037738.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001628280-26-037738 |
| 2026-05-04 | 16:10 ET | [10-Q](/filings/0001628280-26-029802.md) | Quarterly report, period 2026-03-31 | 0001628280-26-029802 |
| 2026-04-30 | 06:53 ET | [8-K](/filings/0001104659-26-052081.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-26-052081 |
| 2026-04-08 | 16:25 ET | [DEF 14A](/filings/0001193125-26-147704.md) | Proxy statement, period 2026-05-26 | 0001193125-26-147704 |
| 2026-02-24 | 16:15 ET | [10-K](/filings/0000310158-26-000063.md) | Annual report, period 2025-12-31 | 0000310158-26-000063 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0000310158-26-000063.md), filed Feb 24, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, locked when the 8-K was accepted. It is scored when the 10-Q or 10-K is ingested. [See the target](/leagues/2026q3/targets/bd69792c-5f45-462f-bd87-3e673376a779)

## About the filer

- CIK: 310158
- Tickers: MRK
- Exchange: NYSE
- SIC code: 2834 Pharmaceutical Preparations
- State of incorporation: NJ
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 29, 2026, 06:44 ET. No prices; not investment advice.